<DOC>
	<DOCNO>NCT00694720</DOCNO>
	<brief_summary>The primary objective study ass activity breathe parameter 4 escalate dos AVE0657 comparison placebo patient Cheynes-Stokes Breathing Syndrome .</brief_summary>
	<brief_title>Evaluation Effect AVE0657 Cheynes-Stokes Breathing Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Cheyne-Stokes Respiration</mesh_term>
	<criteria>Presence Congestive heart failure ( CHF ) define ejection fraction ≤40 % history echocardiography data New York heart Association ( NYHA ) class IIIII typical cyclic crescendo decrescendo change breathe amplitude AHI ≥10 &lt; 60 majority apneas ≥60 % central origin . Subject supplemental oxygen The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Cheyne-stokes breathe</keyword>
</DOC>